Kinin B1 receptor deficiency attenuates cisplatin-induced acute kidney injury by modulating immune cell migration
Carregando...
Citações na Scopus
16
Tipo de produção
article
Data de publicação
2014
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER
Autores
ESTRELA, Gabriel R.
WASINSKI, Frederick
ALMEIDA, Danilo C.
AMANO, Mariane T.
CASTOLDI, Angela
DIAS, Carolina C.
ALMEIDA, Sandro S.
PAREDES-GAMERO, Edgar J.
PESQUERO, Joao B.
Citação
JOURNAL OF MOLECULAR MEDICINE-JMM, v.92, n.4, p.399-409, 2014
Resumo
Cisplatin is a chemotherapeutic agent that causes severe renal dysfunction. The kinin B1 receptor has been associated with the migration of immune cells to injured tissue as well as with renal inflammation. To examine the role of the kinin B1 receptor in cisplatin-induced acute kidney injury, we used kinin B1 receptor knockout mice and treatment with a receptor antagonist before and after cisplatin administration. Cisplatin injection caused exacerbation of renal macrophage and neutrophil migration, higher levels of serum creatinine and blood urea, upregulation of B1 receptor mRNA and an increase in pro-inflammatory cytokines expression. B1 receptor knockout mice exhibited a reduction in serum creatinine and blood urea levels, diminished apoptosis, and decreased cisplatin-induced upregulation of inflammatory components. Moreover, treatment with the B1 receptor antagonist prior to cisplatin administration normalized serum creatinine, blood urea levels, protected from acute tubular necrosis, apoptosis-related genes, and prevented upregulation of pro-inflammatory cytokines. Thus, we propose that kinins have an important role in cisplatin-induced acute kidney injury by impairing immune cells migration to renal tissue during cisplatin nephrotoxicity. <UnorderedList Mark=""Bullet""> <ItemContent> <Para>Kinin B1 receptor is upregulated after cisplatin exposure. Kinin B1 receptor deficiency diminishes the nephrotoxicity caused by cisplatin. Kinin B1 receptor deficiency ameliorates the inflammatory response. Kinin B1 receptor deficiency diminishes apoptosis caused by cisplatin. Kinin B1 receptor antagonism ameliorates renal function after cisplatin injection.
Palavras-chave
Kinins, Nephrotoxicity, Cisplatin, Acute kidney, injury, Inflammation
Referências
- AHLUWALIA A, 1994, EUR J PHARMACOL, V264, P407, DOI 10.1016/0014-2999(94)00503-6
- Araujo RC, 2006, BIOL CHEM, V387, P431, DOI 10.1515/BC.2006.057
- Araujo RC, 2001, BIOL CHEM, V382, P91, DOI 10.1515/BC.2001.014
- Barros CC, 2012, LAB INVEST, V92, P1419, DOI 10.1038/labinvest.2012.105
- Dong X, 2007, KIDNEY INT, V71, P619, DOI 10.1038/sj.ki.5002132
- DRAY A, 1993, TRENDS NEUROSCI, V16, P99, DOI 10.1016/0166-2236(93)90133-7
- Duchene J, 2009, CURR OPIN PHARMACOL, V9, P125, DOI 10.1016/j.coph.2008.11.011
- Faubel S, 2007, J PHARMACOL EXP THER, V322, P8, DOI 10.1124/jpet.107.119792
- Ferreira J, 2002, NEUROPHARMACOLOGY, V43, P1188, DOI 10.1016/S0028-3908(02)00311-8
- Kim HR, 2011, NEPHROLOGY, V16, P545, DOI 10.1111/j.1440-1797.2011.01473.x
- Kimura A, 2012, KIDNEY INT, V82, P1093, DOI 10.1038/ki.2012.240
- Klein J, 2009, FASEB J, V23, P134, DOI 10.1096/fj.08-115600
- Klein J, 2010, J AM SOC NEPHROL, V21, P1157, DOI 10.1681/ASN.2009090887
- Koyama S, 2000, AM J RESP CELL MOL, V22, P75
- Li L, 2008, KIDNEY INT, V74, P1526, DOI 10.1038/ki.2008.500
- Lim SK, 2012, LIFE SCI, V91, P895, DOI 10.1016/j.lfs.2012.07.020
- Lu LH, 2008, J PHARMACOL EXP THER, V324, P111, DOI 10.1124/jpet.107.130161
- Marceau F, 1998, CLIN REV ALLERG IMMU, V16, P385, DOI 10.1007/BF02737658
- Marceau F, 1998, PHARMACOL REV, V50, P357
- McLean PG, 2000, J EXP MED, V192, P367, DOI 10.1084/jem.192.3.367
- Miller RP, 2010, TOXINS, V2, P2490, DOI 10.3390/toxins2112490
- Okusa MD, 2002, NEPHRON, V90, P133, DOI 10.1159/000049032
- Pereira RL, 2011, KIDNEY INT, V79, P1217, DOI 10.1038/ki.2011.14
- PERRETTI M, 1993, AGENTS ACTIONS, V38, pC64, DOI 10.1007/BF01991139
- Pesquero JB, 2000, P NATL ACAD SCI USA, V97, P8140, DOI 10.1073/pnas.120035997
- Ramesh G, 2002, J CLIN INVEST, V110, P835, DOI 10.1172/JCI200215606
- Ramesh G, 2003, AM J PHYSIOL-RENAL, V285, pF610, DOI 10.1152/ajprenal.00101.2003
- Ramesh G, 2004, KIDNEY INT, V65, P490, DOI 10.1111/j.1523-1755.2004.00413.x
- REGOLI D, 1980, PHARMACOL REV, V32, P1
- Sato E, 1996, J IMMUNOL, V157, P3122
- Tadagavadi RK, 2010, J AM SOC NEPHROL, V21, P53, DOI 10.1681/ASN.2009040407
- Wang P, 2008, INT J CLIN EXP MED, V1, P1
- Wang PHM, 2006, INT IMMUNOPHARMACOL, V6, P1960, DOI 10.1016/j.intimp.2006.07.031
- Wang PHM, 2009, INT IMMUNOPHARMACOL, V9, P653, DOI 10.1016/j.intimp.2008.10.018
- Westermann D, 2008, BIOL CHEM, V389, P713, DOI 10.1515/BC.2008.070